[go: up one dir, main page]

BRPI0602351A - método de separação das protéinas fibrinogênio, fator xiii e cola biológica de uma fração plasmática solubilizada e de preparação de concentrados liofilizados das ditas proteìnas - Google Patents

método de separação das protéinas fibrinogênio, fator xiii e cola biológica de uma fração plasmática solubilizada e de preparação de concentrados liofilizados das ditas proteìnas

Info

Publication number
BRPI0602351A
BRPI0602351A BRPI0602351-7A BRPI0602351A BRPI0602351A BR PI0602351 A BRPI0602351 A BR PI0602351A BR PI0602351 A BRPI0602351 A BR PI0602351A BR PI0602351 A BRPI0602351 A BR PI0602351A
Authority
BR
Brazil
Prior art keywords
proteins
fibrinogen
biological glue
solubilized
factor xiii
Prior art date
Application number
BRPI0602351-7A
Other languages
English (en)
Inventor
Michel Nogre
Michel Tellier
Pierre Porte
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of BRPI0602351A publication Critical patent/BRPI0602351A/pt
Publication of BRPI0602351B1 publication Critical patent/BRPI0602351B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/75Fibrinogen
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1025Acyltransferases (2.3)
    • C12N9/104Aminoacyltransferases (2.3.2)
    • C12N9/1044Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

"MéTODO DE SEPARAçãO DAS PROTEìNAS FIBRINOGêNIO, FATOR XIII E COLA BIOLóGICA DE UMA FRAçãO PLASMáTICA SOLUBILIZADA E DE PREPARAçãO DE CONCENTRADOS LIOFILIZADOS DAS DITAS PROTEìNAS". A presente invenção se refere a um método de separação das proteínas fibrinogênio, Fator XIII e cola biológica de uma fração plasmática solubilizada e para a preparação de concentrados liofilizados das ditas proteinas compreendendo as etapas de: purificação cromatográfica compreendendo as etapas de carregar um trocador de ânions do tipo base fraca com a dita fração solubilizada, previamente equilibrada com um tampão de uma força iónica pré-determinada de pH alcalino, que permite reter a cola biológica, a eluição da cola biológica através do aumento da força iónica do dito tampão, e separação do FXIII do fibrinogênio através da adição a ao menos uma parte do eluato da cola biológica de ao menos um agente químico de precipitação do FXIII, e a recuperação do fibrinogênio purificado resultante contendo a solução sobrenadante, e diafiltração das soluções de fibrinogênio, da cola biológica e do FXIII ressolubilizadas, seguida por uma liofilização das ditas soluções. Refere-se também aos concentrados liofilizados das ditas proteínas capazes de serem obtidos pela condução do processo.
BRPI0602351A 2005-06-29 2006-06-26 método de separação das proteínas fibrinogênio, fator xiii e cola biológica de uma fração plasmática solubilizada e de preparação de concentrados liofilizados das ditas proteínas, e, concentrado liofilizado BRPI0602351B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0506640A FR2887883B1 (fr) 2005-06-29 2005-06-29 Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines

Publications (2)

Publication Number Publication Date
BRPI0602351A true BRPI0602351A (pt) 2007-02-21
BRPI0602351B1 BRPI0602351B1 (pt) 2019-01-02

Family

ID=35458225

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0602351A BRPI0602351B1 (pt) 2005-06-29 2006-06-26 método de separação das proteínas fibrinogênio, fator xiii e cola biológica de uma fração plasmática solubilizada e de preparação de concentrados liofilizados das ditas proteínas, e, concentrado liofilizado

Country Status (11)

Country Link
US (3) US8598319B2 (pt)
EP (2) EP1739093B8 (pt)
JP (2) JP5177966B2 (pt)
AU (1) AU2006202680B2 (pt)
BR (1) BRPI0602351B1 (pt)
CA (1) CA2551345C (pt)
DK (1) DK1739093T3 (pt)
ES (1) ES2491215T3 (pt)
FR (1) FR2887883B1 (pt)
IL (2) IL176406A (pt)
PL (1) PL1739093T3 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2894831B1 (fr) 2005-12-16 2008-02-15 Lab Francais Du Fractionnement Colle biologique exempte de thrombine et son utilisation comme medicament.
WO2008113589A1 (en) 2007-03-20 2008-09-25 Csl Behring Gmbh Methods for industrial scale production of therapeutic complement factor h preparations from human plasma
HUE028626T2 (en) 2008-06-23 2016-12-28 Bio-Products & Bio-Engineering Ag Stable, functionally intact, virus-inactivated fibrinogen during storage
KR20160104740A (ko) * 2008-06-24 2016-09-05 옥타파마 아게 응고 인자 viii을 정제하는 방법
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
FR2952641B1 (fr) * 2009-11-18 2012-01-13 Lfb Biomedicaments Procede de traitement du plasma sanguin comprenant une etape de lavage par dispersion
BR112013006384B1 (pt) 2010-09-20 2021-12-07 Octapharma Ag Processo para purificar fibrinogênio a partir de uma fonte contendo fibrinogênio, produto de fibrinogênio e uso de uma resina de troca aniônica
MX351340B (es) 2012-03-13 2017-10-11 Octapharma Ag Proceso mejorado para la produccion de fibrinogeno y fibrinogeno producido por este.
US9932388B2 (en) 2014-11-13 2018-04-03 Hemarus Therapeutics Limited Chromatographic process for producing high purity fibrinogen and thrombin
GB201506117D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
GB201506113D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
US20180169297A1 (en) 2015-06-12 2018-06-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Injectable composition of factor vii and fillers
US20190316133A1 (en) 2016-07-06 2019-10-17 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anti-Fibrinogen Aptamers and Uses Thereof
FR3061020B1 (fr) 2016-12-22 2019-05-17 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Composition de fibrinogene humain
EP3694322B1 (en) 2017-10-09 2024-07-03 Terumo BCT Biotechnologies, LLC Lyophilization container and method of using same
FR3090321B1 (fr) 2018-12-21 2023-07-14 Lab Francais Du Fractionnement Procédé de filtration du fibrinogène
JP7471316B2 (ja) 2019-03-14 2024-04-19 テルモ ビーシーティー バイオテクノロジーズ,エルエルシー マルチパート凍結乾燥容器
CN111518197B (zh) * 2020-03-30 2024-01-05 哈尔滨派斯菲科生物制药有限公司 一种纤维蛋白原的生产方法
KR20230121373A (ko) * 2022-02-11 2023-08-18 주식회사 녹십자 인자 xiii의 정제방법
CN118344463B (zh) * 2024-05-15 2024-12-13 广东丹霞生物制药有限公司 一种人纤维蛋白原的制备方法及产品

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR402001A (fr) 1908-05-02 1909-09-24 Siemens Ag Emploi du tantale pour la confection des instruments chirurgicaux
US4237533A (en) 1978-12-28 1980-12-02 International Business Machines Corporation Preventing initial program load failures
AT359653B (de) 1979-02-15 1980-11-25 Immuno Ag Verfahren zur herstellung eines gewebekleb- stoffes
AT359652B (de) 1979-02-15 1980-11-25 Immuno Ag Verfahren zur herstellung eines gewebekleb- stoffes
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
FR2618784B1 (fr) 1987-07-30 1990-04-06 Lille Transfusion Sanguine Concentre de proteines coagulables par la thrombine, son procede d'obtention et son utilisation a titre de colle biologique
DE3734923C1 (de) * 1987-10-15 1989-01-26 Biotest Pharma Gmbh Verfahren zur Herstellung einer sterilen Plasmaproteinloesung,die Fibrinogen und den Gerinnungsfaktor XIII enthaelt
FR2632309B1 (fr) 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
US5206140A (en) * 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
US5612456A (en) * 1988-11-14 1997-03-18 Zymogenetics, Inc. Factor XIII compositions
JP3415148B2 (ja) 1991-08-07 2003-06-09 ザイモジェネティクス,インコーポレイティド 第x▲iii▼因子の精製
FR2686883B1 (fr) 1992-02-04 1994-05-13 Aquitaine Develop Transf Sanguin Procede de fabrication de fibrinogene de tres haute purete, fibrinogene de tres haute purete obtenu ainsi qu'une composition pharmaceutique le contenant.
CA2162997A1 (en) 1994-03-18 1995-09-28 Daphne C. Tse Topical fibrinogen complex
ATE184884T1 (de) * 1994-07-14 1999-10-15 Croix Rouge De Belgique Fibrinogenkonzentrate aus blutplasma, verfahren und anlage für ihre herstellung
ZA955492B (en) 1994-07-18 1996-02-13 Methanol Casale Sa Catalyst-seal support device in particular for exothermic heterogeneous catalytic synthesis reactors
GB9424732D0 (en) * 1994-12-08 1995-02-08 Common Services Agency Heat treated blood plasma proteins
US5643192A (en) * 1995-04-06 1997-07-01 Hamilton Civic Hospitals Research Development, Inc. Autologous fibrin glue and methods for its preparation and use
AU3495897A (en) 1996-07-24 1998-02-10 Kimberly-Clark Worldwide, Inc. Fibrous sheet materials containing oat extract
US6121232A (en) * 1997-01-31 2000-09-19 Omrix Biopharmaceuticals Sa Stabilized mixture comprising fibrinogen
US5981254A (en) * 1997-10-30 1999-11-09 Haemacure Corporation Process for producing thrombin from plasma
US6815535B1 (en) * 1998-01-23 2004-11-09 Csl Limited Purification of fibrinogen
US7276235B2 (en) * 1998-11-18 2007-10-02 Zlb Behring Gmbh Tissue glue with improved antiadhesive properties
DE60027695T2 (de) 1999-02-12 2007-04-26 Baxter Ag Verfahren zur herstellung von fibrinogen und fibronectin sowie proteinzusammesetzungen, welche damit herstellbar sind
US6610043B1 (en) 1999-08-23 2003-08-26 Bistech, Inc. Tissue volume reduction
CA2394797A1 (en) 1999-12-20 2001-06-28 Tsuyoshi Takahashi Process for producing virus-free plasma protein composition by porous membrane treatment, virus-free plasma protein composition and method of removing viruses
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
WO2001048016A1 (en) * 1999-12-23 2001-07-05 Csl Limited Separation of fibrinogen from plasma proteases
IL136552A (en) 2000-06-05 2005-05-17 Omrix Biopharmaceuticals Ltd Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration
JP2003055257A (ja) * 2001-08-10 2003-02-26 Nihon Pharmaceutical Co Ltd 安定な血液凝固第xiii因子製剤
DE10211632A1 (de) * 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
JP2004057029A (ja) * 2002-07-25 2004-02-26 Sysmex Corp 可溶性フィブリンの調製方法
AT501088A2 (de) * 2002-12-18 2006-06-15 Bio Prod & Bio Eng Ag Stabile therapeutische proteine
ES2214967B1 (es) 2003-03-06 2005-06-16 Probitas Pharma, S.A Procedimiento para la eliminacion de virus en soluciones de fibrinogeno y fibrinogeno obtenido por dicho procedimiento.
DE102004009400A1 (de) 2004-02-24 2005-09-08 Zlb Behring Gmbh Fibrinogen Reinigung
FR2866890B1 (fr) * 2004-02-27 2008-04-04 Lab Francais Du Fractionnement Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant
WO2008113589A1 (en) 2007-03-20 2008-09-25 Csl Behring Gmbh Methods for industrial scale production of therapeutic complement factor h preparations from human plasma

Also Published As

Publication number Publication date
IL241864A0 (en) 2015-11-30
US8598319B2 (en) 2013-12-03
IL176406A0 (en) 2006-10-05
EP2772499A1 (fr) 2014-09-03
EP1739093A1 (fr) 2007-01-03
AU2006202680B2 (en) 2012-03-29
US20140154231A1 (en) 2014-06-05
IL176406A (en) 2015-10-29
BRPI0602351B1 (pt) 2019-01-02
JP2013047273A (ja) 2013-03-07
JP5662988B2 (ja) 2015-02-04
US9339530B2 (en) 2016-05-17
AU2006202680A1 (en) 2007-01-18
US20140148580A1 (en) 2014-05-29
PL1739093T3 (pl) 2014-12-31
ES2491215T3 (es) 2014-09-05
EP1739093B8 (fr) 2014-10-08
JP5177966B2 (ja) 2013-04-10
DK1739093T3 (da) 2014-08-18
FR2887883B1 (fr) 2007-08-31
JP2007008934A (ja) 2007-01-18
FR2887883A1 (fr) 2007-01-05
CA2551345A1 (fr) 2006-12-29
EP1739093B1 (fr) 2014-06-18
US9320779B2 (en) 2016-04-26
CA2551345C (fr) 2014-12-23
US20080207878A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
BRPI0602351A (pt) método de separação das protéinas fibrinogênio, fator xiii e cola biológica de uma fração plasmática solubilizada e de preparação de concentrados liofilizados das ditas proteìnas
Govorukhina et al. Sample preparation of human serum for the analysis of tumor markers: Comparison of different approaches for albumin and γ-globulin depletion
US20200172589A1 (en) Purification of erythropoietin
BRPI0805838A2 (pt) procedimento para a extração de uma proteìna presente no leite
ATE470150T1 (de) Methode zum schnellen identifizieren von kleinen organischen liganden
IL187293A (en) Methods for producing glycosylation proteins at site n and host prokaryotic organisms
BRPI0616712B8 (pt) método para amidar polipeptídeos com terminais c de aminoácido básicos por meio de endoproteases específicas
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
CA2728047A1 (en) A process of purifying coagulation factor viii
BRPI0713252C1 (pt) processo para a recuperação de fator de crescimento endotelial vascular (vegf) recombinante reenovelado
MX348178B (es) Método para purificar adamts13 recombinante y otras proteínas y sus composiciones.
WO2009004315A8 (en) Isolated peptides and uses thereof
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
Lee et al. N-glycan analysis of human α1-antitrypsin produced in Chinese hamster ovary cells
KR20200100771A (ko) 알킬 글리코시드에 의한 단백질 정제 및 바이러스 불활성화
MX2010001482A (es) Proteinas de streptococcus inmunogenicas.
ES2552337T3 (es) Procedimientos para la preparación de plasminógeno
PE20190661A1 (es) Preparacion de derivados del factor xa
Piazza et al. Identification of highly active flocculant proteins in bovine blood
WO2008003707A3 (en) Minimized small peptides with high affinity for factor viii and factor viii-like proteins
WO2007034210A8 (en) Deglycosylated anti-muc-1 antibodies and uses thereof
BR0208786A (pt) Métodod para identificação de proteìnas de bactérias intracelulares
Zhao et al. A practical approach to enrich intact tryptic N-glycopeptides through size exclusion chromatography and hydrophilicity (SELIC) using an acrylamide-agarose composite gel system
DE60327598D1 (de) Trennverfahren mit aromatischen thioetherliganden
Vaisar Thematic review series: proteomics. Proteomic analysis of lipid-protein complexes

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/01/2019, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2625 DE 27-04-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.